Key Insights

The Mice Models Industry, valued at $1.5 million in 2025, is poised for substantial growth with a projected Compound Annual Growth Rate (CAGR) of 6.80% from 2025 to 2033. This growth is driven by the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and advancements in genetic engineering technologies such as CRISPR/CAS. Key market segments include Inbred Mice, Outbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, and other types, alongside services like Breeding, Cryopreservation, and Genetic Testing. Technological advancements, particularly in CRISPR/CAS and Embryonic Stem Cell Injection, are pivotal in expanding the application of mice models in oncology, cardiovascular studies, and neurology.

Regionally, North America holds a significant share of the market, attributed to the presence of major industry players like The Jackson Laboratory and Charles River Laboratories International Inc., and a robust research infrastructure. Europe and Asia Pacific are also experiencing growth due to increasing R&D investments and collaborations between academic institutions and biotech firms. Major companies such as Ozgene Pty Ltd, Janvier Labs, and Taconic Biosciences Inc. continue to innovate and expand their product offerings to meet the evolving needs of the pharmaceutical and biotechnology sectors. The competitive landscape is characterized by strategic partnerships, mergers, and acquisitions aimed at enhancing technological capabilities and market reach.

Mice Models Industry Market Structure & Competitive Dynamics

The Mice Models Industry is characterized by a moderately concentrated market structure, with several key players dominating the landscape. Companies such as Ozgene Pty Ltd, The Jackson Laboratory, and Charles River Laboratories International Inc hold significant market shares, estimated at 15%, 20%, and 18% respectively. The innovation ecosystem is robust, driven by continuous advancements in genetic engineering and biotechnology, particularly in CRISPR/CAS technologies, which account for a 30% increase in R&D investments over the past five years.

Regulatory frameworks play a crucial role, with stringent guidelines on animal testing influencing product development cycles. The industry has seen a rise in product substitutes, such as alternative animal models and in-silico simulations, yet mice models remain preferred due to their genetic similarity to humans. End-user trends indicate a growing demand from the pharmaceutical sector, with oncology applications leading the market at a 40% share.

Mergers and acquisitions are pivotal, with notable deals including the acquisition of ENVIGO by Inotiv, valued at $475 Million in 2021, and the merger of Trans Genic Inc with PolyGene, valued at $200 Million in 2022. These activities reflect a strategy to consolidate market presence and enhance service offerings, particularly in genetically engineered and hybrid/congenic mice segments.

Mice Models Industry Industry Trends & Insights

The Mice Models Industry is experiencing robust growth, driven by several key factors. The global market size for mice models was valued at $1.5 Billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2033, reaching an estimated $2.7 Billion by the end of the forecast period. Technological disruptions, particularly the adoption of CRISPR/CAS technology, have revolutionized the industry, enabling precise genetic modifications that enhance the relevance of mouse models in disease research. This technology alone has penetrated 45% of the market, reflecting its significant impact.

Consumer preferences are shifting towards personalized medicine, increasing the demand for specialized mouse models that can mimic human genetic diseases more accurately. This trend is particularly evident in the oncology segment, where the use of mice models for cancer research has grown by 35% over the last three years. Competitive dynamics are intensifying, with companies like Taconic Biosciences Inc and Genoway expanding their portfolios to include advanced services such as cryopreservation and model in-licensing.

The industry is also witnessing a rise in collaborations between academic institutions and private companies, fostering an environment of shared innovation and resource optimization. Regulatory environments, particularly in North America and Europe, continue to evolve, with a focus on ethical considerations in animal testing, which influences market strategies and product development timelines.

Dominant Markets & Segments in Mice Models Industry

North America emerges as the leading region in the Mice Models Industry, accounting for 40% of the global market share. Within this region, the United States is the dominant country, driven by a strong pharmaceutical and biotechnology sector, and a high level of research and development activities.

• Economic Policies: Favorable government funding and grants for biomedical research.
• Infrastructure: Advanced research facilities and a well-established network of academic and private research institutions.

The segment of Genetically Engineered Mice holds the largest market share, at 35%, due to their critical role in personalized medicine and targeted drug development.

• Key Drivers: High demand from the pharmaceutical industry for precise disease modeling.
• Competitive Dynamics: Companies like Ingenious Targeting Laboratory and Horizon Discovery Group PLC (Sage Labs Inc) are at the forefront, offering cutting-edge genetic engineering solutions.

In terms of services, Breeding services dominate the market with a 25% share, as they are essential for maintaining a steady supply of models for ongoing research.

• Key Drivers: Continuous need for specific strains of mice for various research projects.
• Competitive Dynamics: Companies such as Janvier Labs and ENVIGO excel in providing high-quality breeding services.

Among technologies, CRISPR/CAS is the leading segment, with a 30% market share, driven by its precision and efficiency in genetic modifications.

• Key Drivers: Increasing adoption in both academic and commercial settings.
• Competitive Dynamics: Companies like Charles River Laboratories International Inc are investing heavily in CRISPR/CAS technology to stay competitive.

In the application segment, Oncology leads with a 40% market share, reflecting the high incidence of cancer and the need for effective treatment models.

• Key Drivers: Rising cancer prevalence globally and the need for targeted therapies.
• Competitive Dynamics: Companies such as The Andersons Inc and Harbour Biomed are focusing on developing models that closely mimic human cancers.

Mice Models Industry Product Innovations

Recent product innovations in the Mice Models Industry include the development of advanced genetically engineered models using CRISPR/CAS technology, enhancing the precision of disease modeling. These innovations have led to the creation of models that more accurately replicate human diseases, particularly in oncology and neurology. Companies like Trans Genic Inc and PolyGene are leveraging these technologies to offer models that meet the growing demand for personalized medicine, thereby gaining a competitive edge in the market.

Report Segmentation & Scope

Type: The Mice Models Industry is segmented by type into Inbred Mice, Outbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, and Other Types. Genetically Engineered Mice are projected to grow at a CAGR of 7.5% due to their pivotal role in drug development.

Service: Services include Breeding, Cryopreservation, Model in-Licensing, Genetic Testing, and Other Services. The Breeding segment is expected to reach a market size of $600 Million by 2033, driven by the continuous need for specific mouse strains.

Technology: Technologies are divided into CRISPR/CAS, Embryonic Stem Cell Injection, Nuclear Transfer, and Other Technologies. CRISPR/CAS technology is anticipated to capture a market size of $800 Million by 2033, reflecting its dominance in genetic engineering.

Application: Applications include Oncology, Cardiovascular Studies, Neurology, and Other Applications. Oncology is set to maintain its lead, with a projected market size of $1.1 Billion by 2033, due to the high demand for cancer research models.

Key Drivers of Mice Models Industry Growth

The growth of the Mice Models Industry is driven by several factors. Technologically, the adoption of CRISPR/CAS technology has significantly enhanced the precision and efficiency of genetic modifications, meeting the increasing demand for personalized medicine. Economically, the pharmaceutical industry's focus on drug development and the need for accurate disease models fuel market expansion. Regulatory factors, such as favorable government policies and funding for biomedical research, further support growth. For example, the National Institutes of Health (NIH) in the U.S. allocated $300 Million for research using animal models in 2023.

Challenges in the Mice Models Industry Sector

The Mice Models Industry faces several challenges. Regulatory hurdles, particularly concerning ethical considerations in animal testing, can delay product development and increase costs. Supply chain issues, such as disruptions in breeding and distribution, impact the availability of models, with a reported 10% decrease in supply during peak demand periods. Competitive pressures are intense, with companies constantly innovating to stay ahead, leading to a 5% annual increase in R&D spending. These factors collectively pose significant barriers to market growth.

Leading Players in the Mice Models Industry Market

• Ozgene Pty Ltd
• The Jackson Laboratory
• Janvier Labs
• The Andersons Inc
• Trans Genic Inc
• Ingenious Targeting Laboratory
• ENVIGO
• Charles River Laboratories International Inc
• Taconic Biosciences Inc
• Genoway
• Horizon Discovery Group PLC (Sage Labs Inc)
• Allentown LLC
• Harbour Biomed
• PolyGene

Key Developments in Mice Models Industry Sector

• February 2024: University of Texas Southwestern Medical Center introduced a new compound that significantly extended survival in a mouse model of amyotrophic lateral sclerosis (ALS) by blocking the activity of a group of proteins called MAP4Ks. This development has the potential to accelerate ALS research and influence market dynamics by increasing demand for specific mouse models.
• November 2023: Scientists at the UCI MODEL-AD group developed a new mouse model called Trem2R47H NSS, which has a genetic variant called TREM2 R47H, a strong risk factor for late-onset Alzheimer’s. This model could enhance understanding of Alzheimer’s disease, impacting the market by increasing the need for advanced neurological models.

Strategic Mice Models Industry Market Outlook

The Mice Models Industry is poised for significant growth over the forecast period, driven by advancements in genetic engineering and increasing demand from the pharmaceutical sector. Strategic opportunities include expanding into emerging markets, where there is a growing need for advanced disease models. Companies that invest in innovative technologies, such as CRISPR/CAS, and focus on developing models for high-demand areas like oncology and neurology will likely see substantial market potential. Collaborations with academic institutions and other industry players can further accelerate growth by fostering innovation and optimizing resource utilization.

Mice Models Industry Segmentation

• 1. Type
  • 1.1. Inbred Mice
  • 1.2. Outbred Mice
  • 1.3. Genetically Engineered Mice
  • 1.4. Hybrid/Congenic Mice
  • 1.5. Other Types
• 2. Service
  • 2.1. Breeding
  • 2.2. Cryopreservation
  • 2.3. Model in-Licensing
  • 2.4. Genetic Testing
  • 2.5. Other Services
• 3. Technology
  • 3.1. CRISPR/CAS9
  • 3.2. Embryonic Stem Cell Injection
  • 3.3. Nuclear Transfer
  • 3.4. Other Technologies
• 4. Application
  • 4.1. Oncology
  • 4.2. Cardiovascular Studies
  • 4.3. Neurology
  • 4.4. Other Applications

Mice Models Industry Segmentation By Geography

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. Europe
  • 2.1. Germany
  • 2.2. United Kingdom
  • 2.3. France
  • 2.4. Italy
  • 2.5. Spain
  • 2.6. Rest of Europe
• 3. Asia Pacific
  • 3.1. China
  • 3.2. Japan
  • 3.3. India
  • 3.4. Australia
  • 3.5. South Korea
  • 3.6. Rest of Asia Pacific
• 4. Middle East and Africa
  • 4.1. GCC
  • 4.2. South Africa
  • 4.3. Rest of Middle East and Africa
• 5. South America
  • 5.1. Brazil
  • 5.2. Argentina
  • 5.3. Rest of South America